On 2 April 2024, Korea Biomedical Review reported Samsung Bioepis’ Korean launch of Epysqli®, biosimilar to AstraZeneca’s Soliris® (eculizumab), with a 30% price reduction. Soliris®, developed by Alexion Pharmaceuticals and marketed by AstraZeneca, is used for the treatment of rare conditions such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. The annual cost for treatment with Soliris® is approximately 400 million won per patient.
Samsung Bioepis launched Epysqli® in three European countries on 19 October 2023. Epysqli® was approved by the EMA on 30 May 2023.